



NEWS RELEASE

FOR IMMEDIATE RELEASE

Contact: Ronald C. Trahan, APR, President, Ronald Trahan Associates Inc., +1-508-816-6730

Stentys drug-eluting *self-expanding* coronary stent shows 4% restenosis in complex lesions

Long-term follow-up data in Stentys DES and BMS clinical study shows superior results in the treatment of bifurcations

PRINCETON, N.J., and PARIS, Feb. 15, 2010—Medical device pioneer **Stentys** announced today that the complete ‘**OPEN-I**’ clinical study was presented by **Stefan Verheye, M.D., Ph.D.**, at the **Joint Interventional Meeting (“JIM”) 2010** in Rome, demonstrating superior results in **60 patients (27 Stentys drug-eluting stents and 33 Stentys bare-metal stents)** who were followed-up angiographically after six months.

“These clinical results suggest very promising benefits for patients,” said **Stefan Verheye, M.D., Ph.D.**, Department of Cardiology, Middelheim Hospital, Antwerp, Belgium. “We had already demonstrated that the *self-expanding* and *disconnectable* Stentys platform ensured optimal wall apposition and easy access to side branches. We can now confirm that the addition of a drug coating eliminates the need for reintervention.”

“These data fortify our conviction of the indisputable superiority of Stentys self-expanding and drug-eluting stents over balloon-expandable DES for the treatment of complex cases,” added **Gonzague Issenmann, CEO and co-founder of Stentys**. “We are actively pursuing our clinical program, particularly in the treatment of Acute Myocardial Infarction, to also prove the superiority of the Stentys technology in this additional group of patients.”

About Stentys

Based in Princeton, N.J., and Paris, [Stentys](#) intends to make treatment of complex blocked coronary arteries as simple and effective as a conventional stenting procedure. The Company announced in December 2009 that it has started enrolling patients in the randomized **APPOSITION II** clinical trial to compare the Stentys *self-expanding* stent against conventional stents in treating AMI patients, looking specifically at stent apposition and adaptation to vessel growth. Stentys was co-founded by [Gonzague Issenmann](#) and [Jacques Séguin, M.D., Ph.D., founder of CoreValve](#), which was acquired last year by Medtronic for \$700 million plus earn-outs.

#####